Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Local Monotherapy of REOLYSIN for Patients with Recurrent Malignant Gliomas

Next Previous
Trial Profile

Local Monotherapy of REOLYSIN for Patients with Recurrent Malignant Gliomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary)
  • Indications Glioma
  • Focus Adverse reactions

Most Recent Events

  • 27 Apr 2015 New trial record
  • 17 Apr 2015 According to an Oncolytics Biotech media release, the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for pelareorep [Reolysin], for the treatment of malignant glioma. The Company had applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top